CCR1 Inhibitors -Pipeline Insights, 2015

“Summary
DelveInsight’s, CCR1 Inhibitors- Pipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the CCR1 Inhibitors. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The CCR1 Inhibitors Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, CCR1 Inhibitors- Pipeline Insights, 2015 Report covers the CCR1 Inhibitors pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides CCR1 Inhibitors related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for CCR1 Inhibitors.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
”
“Scope
– DelveInsight’s report provides a CCR1 Inhibitors Landscape across the globe
– The report provides drug profiles which includes product description, MOA, licensors & collaborators, technology, development partner and chemical information
– Coverage of the CCR1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
– The report reviews key players involved in the therapeutics development for CCR1 Inhibitors and also provide company profiling
– Pipeline products coverage based on various stages of development from NDA filings to discovery.
– Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
”
“Reasons to buy
– Complete Pipeline intelligence and complete understanding over therapeutics development for CCR1 Inhibitors
– Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
– Track your competitors and develop strategic initiatives to support your drug development activities.
– Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
– Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
– Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned
”

“• CCR1 Inhibitors Overview
• CCR1 Inhibitors Disease Associated
• CCR1 Inhibitors Pipeline Therapeutics
• CCR1 Inhibitors Therapeutics under Development by Companies 
• CCR1 Inhibitors Late Stage Products (Filed and Phase III)
• Comparative Analysis 
• CCR1 Inhibitors Mid Clinical Stage Products (Phase II)
• Comparative Analysis 
• CCR1 Inhibitors Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis 
• CCR1 Inhibitors Discovery and Pre-Clinical Stage Products 
• Comparative Analysis 
• Drug Candidate Profiles
• CCR1 Inhibitors – Therapeutics Assessment 
• Assessment by Monotherapy Products 
• Assessment by Combination Products 
• Assessment by Route of Administration 
• Assessment by Molecule Type 
• CCR1 Inhibitors – Discontinued Products 
• CCR1 Inhibitors – Dormant Products
• Companies Involved in Therapeutics Development for CCR1 Inhibitors 
• Appendix 
• Methodology 
• Contact Us 
• Disclaimer”
“• Number of Products under Development for CCR1 Inhibitors by Therapy Area, 2015
• Number of Products under Development for CCR1 Inhibitors, 2015
• Number of Products under Development by Companies 
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• CCR1 Inhibitors Assessment by Monotherapy Products 
• CCR1 Inhibitors Assessment by Combination Products 
• CCR1 Inhibitors Assessment by Route of Administration 
• CCR1 Inhibitors Assessment by Stage and Route of Administration 
• CCR1 Inhibitors Assessment by Molecule Type 
• CCR1 Inhibitors Assessment by Stage and Molecule Type 
• CCR1 Inhibitors Therapeutics – Discontinued Products 
• CCR1 Inhibitors Therapeutics – Dormant Products
• Products under Development by Companies, 2015″
“• Number of Products under Development for CCR1 Inhibitors by Therapy Area, 2015
• Number of Products under Development for CCR1 Inhibitors, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• CCR1 Inhibitors Assessment by Monotherapy Products 
• CCR1 Inhibitors Assessment by Combination Products 
• CCR1 Inhibitors Assessment by Route of Administration 
• CCR1 Inhibitors Assessment by Stage and Route of Administration 
• CCR1 Inhibitors Assessment by Molecule Type 
• CCR1 Inhibitors Assessment by Stage and Molecule Type”